QuidelOrtho Q2 2026 earnings report shows revenue at $631M, down 2%, with significant declines in China affecting guidance and market outlook.
QuidelOrtho Corporation reported Q2 2026 total revenue of $631 million, a 2% increase on a constant currency basis but down from expectations due to significant headwinds in China and a soft respiratory market. Management's outlook has turned cautious, revising full-year guidance to reflect ongoing challenges impacting customer demand.
Key Takeaways
- Total revenue reached $631 million, a 2% increase year-over-year, negatively impacted by a 23% revenue decline in China.
- Adjusted EBITDA rose 21% to $129 million, with EBITDA margin expanding 310 basis points to 20% of revenue.
- Adjusted EPS was reported at 13 cents, signaling resilience despite market pressures.
- Full-year revenue guidance revised to $2.52 billion to $2.60 billion, reflecting cautious assumptions for respiratory season demand and ongoing issues in China.
- Free cash flow guidance withdrawn due to uncertainty around working capital implications and market conditions.
Revenue Decline Driven by China and Respiratory Weakness
Total revenue for the quarter increased by 2% year-over-year, primarily supported by robust performance outside of China, where revenue grew 6%. However, the company faced a significant 23% decline in the Chinese market, where uncertainty surrounding new in vitro diagnostic (IVD) pricing guidelines has led to reduced inventory purchases by customers.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Total Revenue | $631M | +2% | - |
| Adjusted EBITDA | $129M | +21% | - |
| Adjusted EPS | $0.13 | - | - |
Brian Blaser, CEO, noted, “While we are navigating significant headwinds in China and a softer respiratory environment, the underlying performance of our business remains strong.” He emphasized the growth in Labs and immunohematology revenue outside of China, which rose by 9% and 5%, respectively.
Cautious Full-Year Outlook
Given the challenges in China and the anticipated softness in the respiratory season, management revised the full-year revenue guidance down to a range of $2.52 billion to $2.60 billion. This adjustment reflects a more conservative approach based on current market conditions. The company expects adjusted EBITDA for the year to be in the range of $540 million to $560 million, with an EBITDA margin between 21% and 22%. Adjusted EPS is now forecasted to be between 65 cents and 90 cents.
Micah Young, the new CFO, stated, “Our focus remains on executing with discipline, responding appropriately to current conditions and positioning QuidelOrtho for stronger, more sustainable performance over the long term.” He also acknowledged the withdrawal of free cash flow guidance due to uncertainty in market dynamics and their impact on cash generation.
Mitigation Strategies Underway
In light of the challenges, management is actively implementing mitigation strategies, particularly in China, to safeguard customer relationships and adjust commercial plans. Blaser indicated that the company is working closely with customers and distribution partners to navigate the evolving reimbursement environment. The company is also enhancing its operational efficiency to improve cash conversion and reduce leverage.
During the Q&A, Blaser responded to questions about the potential sale of the point-of-care business, stating, “Our highest priority is maximizing long-term shareholder value,” while emphasizing that the management team is regularly evaluating various opportunities to strengthen the business.
Frequently Asked Questions
Did QuidelOrtho Corporation Common Stock beat earnings estimates in Q2 2026?
No, QuidelOrtho's adjusted EPS of 13 cents fell short of consensus estimates of 15 cents, reflecting the impact of market headwinds.
What is the revised full-year revenue guidance for QuidelOrtho in 2026?
The revised full-year revenue guidance is now set between $2.52 billion and $2.60 billion, down from previous expectations due to market pressures in China and a cautious outlook on respiratory season demand.
How did the company's revenue perform outside of China in Q2 2026?
Revenue outside of China grew by 6% year-over-year, demonstrating the resilience of QuidelOrtho's core business segments, particularly in Labs and immunohematology.
What are the company's priorities moving forward?
QuidelOrtho's priorities include improving cash conversion, reducing leverage, and maintaining a disciplined capital allocation approach to enhance long-term shareholder value amidst current market challenges.
In summary, while QuidelOrtho Corporation is encountering significant challenges, particularly in its Chinese market and respiratory revenue expectations, it remains committed to leveraging its core strengths and executing strategic initiatives for resilience and growth.
This analysis is based on public earnings call materials and is not investment advice.
